Health2 years ago
Tsucatinib added to primary maintenance during investigation of HER2 + metastatic breast cancer
The addition of tucatinib to the maintenance of standard of care in the first-line setting of patients with HER2-positive metastatic breast cancer will be considered in...
Recent Comments